Pharnext (PNEXF) Stock Price, News & Analysis

Company Overview

Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.

Key Stats

• Today's Range: $400.00 to $400.00
• 50-Day Range: $400.00 to $400.00
• 52-Week Range: $0.0001 to $0.0010
• Volume: 16,660 shs
• Average Volume: 433 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PNEXF Stock Analysis - Frequently Asked Questions

How have PNEXF shares performed this year?

Pharnext's stock was trading at $400.00 at the start of the year. Since then, PNEXF stock has increased by 0.0% and is now trading at $400.00.
View the best growth stocks for 2025 here.

When did Pharnext's stock split?

Pharnext's stock reverse split on Thursday, February 15th 2024. The 1-10000 reverse split was announced on Thursday, February 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Pharnext?

Shares of PNEXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PNEXF
• CIK: N/A
• Web: www.pharnext.com
• Phone: (314) 109-2230
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A